← FDA DRUG APPROVALS

FDA ANDA · ANDA062225

NYSTATIN

Sponsor: PADAGIS US

APPLICATION
ANDA062225
TYPE
ANDA
ORIGINAL APPROVAL
1979-12-11
LATEST ACTION
2009-12-03
ROUTE
TOPICAL
DOSAGE FORM
CREAM
MARKETING STATUS
Prescription

Products

NYSTATINPrescription
NYSTATIN 100,000 UNITS/GM · CREAM · TOPICAL

Approval history

2009-12-03Labeling · Supplement 11AP
2009-04-17Labeling · Supplement 10AP
2000-09-05Manufacturing (CMC) · Supplement 8AP
1995-06-15Manufacturing (CMC) · Supplement 6AP
1995-06-15Manufacturing (CMC) · Supplement 7AP
1994-07-06Labeling · Supplement 4AP
1993-10-04Labeling · Supplement 5AP
1988-03-18Manufacturing (CMC) · Supplement 3AP
1979-12-11OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →